Products
Imepitoin is commercially available in tablet form (Pexion). It has been approved in many countries since 2013.
Structure and properties
Imepitoin (C13H14ClN3O2, Mr = 279.7 g/mol) is a morpholine and imidazolone derivative. It is structurally unrelated to the benzodiazepines.
Effects
Imepitoin (ATCvet QN03AX90) has antiepileptic properties. Its effects are due to partial agonism with low affinity for the benzodiazepine receptor. Like the benzodiazepines, it potentiates the effects of GABA, the major inhibitory neurotransmitter in the brain. Imepitoin is also a weak calcium channel blocker, which may contribute to its efficacy.
Indications
To reduce the frequency of generalized seizures in idiopathic epilepsy in dogs.
Dosage
According to the SmPC. Tablets are administered twice daily, 12 hours apart and preferably fasting.
Contraindications
Imepitoin is contraindicated in hypersensitivity, severe hepatic or renal impairment, or severe cardiovascular impairment. For complete precautions, see the drug label.
Interactions
There are no known interactions with other drugs.
Adverse effects
Possible adverse effects include increased food intake, hyperactivity, increased urine output, drowsiness, increased salivation, vomiting, movement disorders, apathy, diarrhea, prolapse of the nictitating membrane, impaired vision, and sensitivity to sound.
